You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care ApplicationsSBC: GENECAPTURE, INC. Topic: CBD15C001
The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust moleculaSTTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare ApplicationsSBC: GENECAPTURE, INC. Topic: CBD15C001
GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we p ...STTR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: Flow Pharma, Inc. Topic: CBD18A002
Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: CFD RESEARCH CORPORATION Topic: CBD18A001
In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense